GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Cognition Therapeutics
Shares of Cognition Therapeutics, a biotech company focused on treating Alzheimer's disease, reflect the sector's binary risks. The price trajectory depends entirely on the results of clinical trials and regulatory decisions regarding its drugs.
Share prices of companies in the market segment - Neuro
Cognition Therapeutics, Inc. is a biopharmaceutical company developing drugs to treat neurodegenerative diseases, such as Alzheimer's, by targeting synaptic function. We classify it in the Neuroscience segment, where it seeks new treatment approaches. The chart below illustrates the dynamics of this complex sector.
Broad Market Index - GURU.Markets
Cognition Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the broader market.
Change in the price of a company, segment, and market as a whole per day
CGTX - Daily change in the company's share price Cognition Therapeutics
The daily price fluctuations of Cognition Therapeutics, a company developing drugs for Alzheimer's disease, are a measure of its enormous volatility. This indicator reflects extreme sensitivity to clinical trial data and is key to the biotech risk assessment formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Neuro
Cognition Therapeutics, Inc. is a biotech company. This chart shows the sector's extreme volatility. Comparison with CGTX, which focuses on Alzheimer's disease treatments, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Cognition Therapeutics is fighting Alzheimer's disease at the forefront of neuroscience. The company's shares represent a bet on scientific breakthroughs, and their high volatility is driven by research news. These movements are part of a broader market dynamic where science and finance intertwine.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Cognition Therapeutics
Cognition Therapeutics' year-to-date performance is a story about developing a new approach to treating Alzheimer's disease. Its 12-month market cap depends entirely on clinical trial data for its oral drug, which targets toxic beta-amyloid oligomers. Success in this highly complex area could be a true breakthrough.
Annual dynamics of market capitalization of the market segment - Neuro
Cognition Therapeutics, Inc. is a clinical-stage biotech company developing drugs to treat neurodegenerative diseases such as Alzheimer's. Its stock price is entirely dependent on clinical trial results. The chart reflects both enormous potential and significant risks.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Cognition Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Cognition Therapeutics
Cognition Therapeutics is focused on finding treatments for Alzheimer's disease, one of the riskiest areas of biotech. Its monthly price fluctuations are almost entirely driven by clinical trial data. The chart reflects the high hopes and binary risks associated with development in this complex field.
Monthly dynamics of market capitalization of the market segment - Neuro
Cognition Therapeutics develops drugs to treat neurodegenerative diseases such as Alzheimer's by targeting specific protein receptors in the brain. The graph below illustrates the overall dynamics in the neuroscience sector, where the need for effective drugs is enormous, but the risk of clinical failure is also very high.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Alzheimer's drug development is one of the riskiest areas in biotech. The chart below shows the overall risk appetite. Is Cognition Therapeutics moving with the flow, or is its stock solely dependent on clinical trial data?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Cognition Therapeutics
Shares of Cognition Therapeutics, a company focused on fighting Alzheimer's disease, reflect the weekly volatility of the biotech sector. Price movements directly respond to any news about the progress of their drug's clinical trials, where the stakes for investors and patients are extremely high.
Weekly dynamics of market capitalization of the market segment - Neuro
Cognition Therapeutics fights neurodegenerative diseases such as Alzheimer's. News of clinical trials in this area triggers a strong market reaction. The chart below helps differentiate investor reactions to the company's own data from the general optimism or pessimism sweeping the sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Cognition Therapeutics develops drugs to treat Alzheimer's disease. Shares of such innovative biotech companies often move independently of the market. This chart will help you understand: is Cognition Therapeutics living in its own world of clinical trials, or is the overall market environment influencing its stock price?
Market capitalization of the company, segment and market as a whole
CGTX - Market capitalization of the company Cognition Therapeutics
Cognition Therapeutics' market capitalization, like Alpha Cognition's, tells the story of a risky but potentially breakthrough Alzheimer's drug development. Its volatile chart is a heartbeat of hopes associated with its unique treatment approach. Its dynamics reflect investors' assessment of each new set of clinical trial data.
CGTX - Share of the company's market capitalization Cognition Therapeutics within the market segment - Neuro
Cognition Therapeutics is a clinical-stage biopharmaceutical company developing treatments for neurodegenerative diseases such as Alzheimer's disease and Lewy body dementia. Its market cap reflects the potential of its unique approach. The chart below shows how investors view its chances in this challenging area of medicine.
Market capitalization of the market segment - Neuro
Cognition Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases such as Alzheimer's. The chart below shows the market capitalization of this complex sector. Its dynamics tell the story of hopes and disappointments in the search for a cure for one of humanity's most complex diseases.
Market capitalization of all companies included in a broad market index - GURU.Markets
Cognition Therapeutics develops drugs to treat neurodegenerative diseases such as Alzheimer's. Its valuation reflects the hope that its unique approach can halt or slow memory loss. Its volatility reflects the immense complexity and importance of this medical problem.
Book value capitalization of the company, segment and market as a whole
CGTX - Book value capitalization of the company Cognition Therapeutics
Cognition Therapeutics' balance sheet is the capital invested in clinical trials of small molecules aimed at treating Alzheimer's disease and other neurodegenerative disorders. This provides a tangible, scientific foundation for finding a cure for memory loss. How has this risky biotech asset changed? The chart below shows its dynamics.
CGTX - Share of the company's book capitalization Cognition Therapeutics within the market segment - Neuro
Cognition Therapeutics develops drugs for neurodegenerative diseases, which requires research laboratories. The chart shows the share of these research-intensive tangible assets, reflecting the physical foundation upon which the company is fighting Alzheimer's disease.
Market segment balance sheet capitalization - Neuro
Cognition Therapeutics is fighting Alzheimer's disease. Its business is science, not manufacturing. Its main assets are patents. The book value chart will show how "weightless" the company's financial base is, working on one of the most complex problems in medicine.
Book value of all companies included in the broad market index - GURU.Markets
Cognition Therapeutics combats memory loss in neurodegenerative diseases. Its book value is represented by its laboratories and capital invested in clinical trials of drugs aimed at protecting synapses. The chart shows the resources on which the company is building its search for a solution to one of the most complex problems in medicine.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Cognition Therapeutics
Cognition Therapeutics' balance sheet is capital. But investors see hope in a cure for Alzheimer's disease. The chart shows the "hope multiple": the premium the market is paying for the drug's potential to protect the brain from deterioration. This is a clear bet on success in one of the most complex areas of medicine.
Market to book capitalization ratio in a market segment - Neuro
Cognition Therapeutics develops drugs to treat neurodegenerative diseases such as Alzheimer's. Its value is based on the potential of its scientific research. The chart demonstrates investors' enormous faith in its ability to succeed in this highly complex field.
Market to book capitalization ratio for the market as a whole
Cognition Therapeutics develops drugs to treat neurodegenerative diseases like Alzheimer's by targeting specific receptors in the brain. The company's assets are its scientific hypothesis and data. This chart shows the overall valuation, but how do investors view this latest attempt to find the key to treating one of the most enigmatic diseases?
Debts of the company, segment and market as a whole
CGTX - Company debts Cognition Therapeutics
Cognition Therapeutics, a biotech company focused on Alzheimer's disease, is tackling a complex scientific challenge. This chart illustrates the enormous financial resources and time required to develop and test drugs to combat this devastating disease.
Market segment debts - Neuro
Cognition Therapeutics develops drugs to combat neurodegenerative diseases like Alzheimer's by targeting specific protein receptors. This chart shows how the company is funding its long-term, high-risk research in pursuit of a solution to one of medicine's most complex problems.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Cognition Therapeutics
Cognition Therapeutics is tackling neurodegenerative diseases by developing next-generation drugs. This chart illustrates the company's reliance on external funding to advance its candidates through clinical trials. It highlights the financial risk involved in the long and uncertain path to a cure for Alzheimer's disease.
Market segment debt to market segment book capitalization - Neuro
Cognition Therapeutics develops drugs targeting beta-amyloid oligomers to treat neurodegenerative diseases. This chart shows the overall debt burden in the neuroscience sector. It helps understand how the industry finances risky and lengthy clinical trials, and how Cognition Therapeutics manages its capital in this complex field.
Debt to book value of all companies in the market
Cognition Therapeutics is tackling neurodegenerative diseases by targeting their root causes. It's a long and uncertain journey, financed entirely by equity. A chart depicting debt trends in the economy illustrates that the company's financial model is focused on scientific breakthroughs rather than leveraged management.
P/E of the company, segment and market as a whole
P/E - Cognition Therapeutics
This chart for Cognition Therapeutics, a company developing drugs for Alzheimer's disease, shows the high stakes investors are placing. The multiple is based on the enormous unmet need for treatments for neurodegenerative diseases. This is the price paid for the hope of clinical success, which comes with extremely high risks.
P/E of the market segment - Neuro
Alzheimer's disease treatment, as pursued by Cognition Therapeutics, is a highly risky area. This chart shows the average valuation for biopharmaceutical companies. It makes clear that Cognition's valuation depends entirely on investor confidence in its unique treatment approach and clinical trial data, making it highly volatile.
P/E of the market as a whole
Cognition Therapeutics develops drugs for the treatment of neurodegenerative diseases, such as Alzheimer's, targeting a new class of targets. A potential breakthrough in this field could change the world. This chart of overall risk appetite is an indicator of whether investors are willing to make long-term bets on such high-risk scientific projects.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Cognition Therapeutics
Cognition Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases such as Alzheimer's. This chart illustrates the high but risky expectations associated with clinical trials. The trend reflects investors' assessment of the chances of success in this complex field.
%20P%2FE%20Cognition%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Cognition-Therapeutics&v=1772513911413 "Chart of the company's future (projected) P/E Cognition Therapeutics")
Future (projected) P/E of the market segment - Neuro
Cognition Therapeutics develops drugs to treat neurodegenerative diseases such as Alzheimer's by targeting specific receptors in the brain. This chart shows profitability expectations for the neuroscience sector. It provides insight into how the market views the company's unique scientific approach to treating complex brain diseases.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772513911462 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Cognition Therapeutics develops drugs to treat neurodegenerative diseases such as Alzheimer's by targeting toxic beta-amyloid oligomers. This chart illustrates investors' risk appetite. For a company targeting one of the most complex medical challenges, it reflects the market's willingness to fund high-risk scientific projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513911466 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Cognition Therapeutics
Cognition Therapeutics develops drugs to treat neurodegenerative diseases such as Alzheimer's by targeting specific protein receptors. The financial metrics presented here reflect clinical trial costs. The chart illustrates the financial risks and potential of a company working to solve one of the biggest medical problems.
Profit of companies in the market segment - Neuro
Cognition Therapeutics develops drugs to treat neurodegenerative diseases such as Alzheimer's by targeting toxic beta-amyloid oligomers. The company's success hinges on clinical data. This graph reflects the enormous risks and potential in neuroscience, where effective treatments could generate billions of dollars in revenue and change lives.
Overall market profit
Cognition Therapeutics develops drugs to treat neurodegenerative diseases such as Alzheimer's. This is a high-risk, high-reward field. Funding for such breakthrough research depends directly on investor risk appetite, which is highest during periods of economic growth and high corporate profitability, as shown in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Cognition Therapeutics
Cognition Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's. The profit/loss forecast in this chart reflects the high cost of research and analysts' expectations for clinical trial results in one of the most complex areas of medicine.
%20profit%20of%20the%20company%20Cognition%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Cognition-Therapeutics&v=1772513911663 "Graph of future (projected) profit of the company Cognition Therapeutics")
Future (predicted) profit of companies in the market segment - Neuro
Cognition Therapeutics develops drugs to treat neurodegenerative diseases such as Alzheimer's by targeting toxic beta-amyloid oligomers. This chart shows the revenue forecast for the neuroscience sector, providing context for assessing Cognition Therapeutics' scientific approach and commercial prospects in this complex area of medicine.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772513911667 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Cognition Therapeutics is a biotech company focused on treating neurodegenerative diseases. Its valuation is determined by the potential of its scientific developments. This graph, reflecting overall market sentiment, influences the availability of venture capital required to conduct lengthy and expensive clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513911668 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Cognition Therapeutics
Cognition Therapeutics develops drugs to treat neurodegenerative diseases such as Alzheimer's by targeting specific receptors. This chart reflects investors' expectations for clinical success. The valuation is a bet on its unique scientific approach in a highly complex field.
P/S market segment - Neuro
Cognition Therapeutics develops drugs to treat neurodegenerative diseases such as Alzheimer's by preventing toxic proteins from binding to brain cells. This chart shows the biotech industry's average price-to-sales ratio. It reflects investor expectations for the company's innovative approach to treating these complex diseases.
P/S of the market as a whole
Cognition Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's by targeting beta-amyloid oligomers. This chart helps understand how the market is pricing high-risk but potentially revolutionary approaches to treating today's most complex diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Cognition Therapeutics
Cognition Therapeutics develops drugs to treat neurodegenerative diseases such as Alzheimer's. This chart shows its valuation relative to future projected sales. It provides a measure of investor confidence in the success of its unique approach to treating these complex diseases.
%20P%2FS%20Cognition%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Cognition-Therapeutics&v=1772513911672 "The graph of the company's future (projected) P/S Cognition Therapeutics")
Future (projected) P/S of the market segment - Neuro
Cognition Therapeutics develops drugs to treat neurodegenerative diseases such as Alzheimer's by targeting toxic beta-amyloid oligomers. This chart reflects investor expectations for the company's potential breakthrough in this complex area of medicine and its future revenue compared to other neurobiotech companies.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772513911704 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Cognition Therapeutics is a biopharmaceutical company focused on treating neurodegenerative diseases. Its value is based on the potential of its research to combat Alzheimer's disease. This general expectations chart for CGTX is not a direct driver. The company operates in an area with a huge unmet need, independent of the economy.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513911735 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Cognition Therapeutics
This chart illustrates the financial trajectory of a biotech company. For Cognition Therapeutics, which focuses on treating neurodegenerative diseases such as Alzheimer's, it reflects funds raised from investors and grants to fund expensive clinical trials.
Sales of companies in the market segment - Neuro
Cognition Therapeutics develops drugs to treat neurodegenerative diseases such as Alzheimer's, targeting beta-amyloid oligomers. Success could be a breakthrough. This chart shows revenue in neurology. Potential approval of Cognition's drug would not only change lives but also create a huge new market.
Overall market sales
Cognition Therapeutics develops drugs to treat neurodegenerative diseases such as Alzheimer's. The company is targeting one of the greatest unmet needs in medicine. Its research is part of a global effort to combat these diseases, and advances in this field will have a profound impact on healthcare and the economy.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Cognition Therapeutics
Cognition Therapeutics develops drugs to treat neurodegenerative diseases such as Alzheimer's by targeting beta-amyloid oligomers. Future sales projections depend on the success of its clinical programs. This graph reflects expectations in this high-risk, yet socially significant, field.
%20sales%20of%20the%20company%20Cognition%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Cognition-Therapeutics&v=1772513911776 "Schedule of future (projected) sales of the company Cognition Therapeutics")
Future (projected) sales of companies in the market segment - Neuro
Cognition Therapeutics develops drugs to treat neurodegenerative diseases such as Alzheimer's. The outlook for the neuroscience sector reflects the enormous need for effective treatments. The chart demonstrates the market's hunger for breakthroughs in this field, creating significant potential for successful developments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772513911795 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Cognition Therapeutics is a biopharmaceutical company developing drugs for the treatment of neurodegenerative diseases. The company's prospects depend on the success of its clinical programs. The need for an effective treatment for Alzheimer's disease is enormous and is not dependent on economic cycles, but this timeframe may impact the availability of funding for long-term research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513911810 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Cognition Therapeutics
Cognition Therapeutics is a biopharmaceutical company developing drugs to treat neurodegenerative diseases such as Alzheimer's. Being in the clinical stage, it incurs high R&D costs. This chart shows the "cost of innovation"—the amount of investment the company is making to combat this complex disease.
Market segment marginality - Neuro
Cognition Therapeutics develops drugs to treat neurodegenerative diseases such as Alzheimer's by targeting specific receptors. Profitability depends on the success of clinical trials. This chart shows the company's investment in its unique scientific platform compared to other neuroscience firms.
Market marginality as a whole
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company targeting neurodegenerative diseases such as Alzheimer's. This chart shows the company's total profit margin. Compared to this, Cognition is a high-risk bet on a breakthrough in one of the most complex areas of medicine. Its future depends on the results of its clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company Cognition Therapeutics
Cognition Therapeutics is a clinical-stage company focused on fighting Alzheimer's disease. Its small but highly specialized team is advancing its drugs through clinical trials. The growth this graph could show would indicate positive data and expanded research, which is critical for companies like this.
Share of the company's employees Cognition Therapeutics within the market segment - Neuro
Cognition Therapeutics develops drugs for the treatment of neurodegenerative diseases, such as Alzheimer's, that target unique receptors. This chart illustrates its scientific focus. It reflects the percentage of neuroscientists and chemists specializing in finding new targets for the treatment of age-related brain diseases that Cognition attracts.
Number of employees in the market segment - Neuro
Cognition Therapeutics is developing drugs to combat neurodegenerative diseases by targeting beta-amyloid oligomers. This graph illustrates a targeted approach to treating Alzheimer's disease. The growth of the research team here reflects progress in clinical trials testing this specific and promising hypothesis.
Number of employees in the market as a whole
Cognition Therapeutics develops drugs to combat neurodegenerative diseases. Like many biotech companies, they operate in their own cycle, driven by science. This overall employment schedule doesn't influence their hiring decisions. Their primary focus is progress in clinical trials, which unlocks funding for further research.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Cognition Therapeutics (CGTX)
Cognition Therapeutics develops drugs to treat neurodegenerative diseases such as Alzheimer's by targeting the early stages of the pathological process. This chart shows how the market values the biotech. The high market cap per employee reflects the potential value of solving one of the biggest healthcare problems, not the company's size.
%20of%20the%20company%20Cognition%20Therapeutics%20(CGTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Cognition-Therapeutics-CGTX&v=1772513912020 "Chart of market capitalization per employee (in thousands of dollars) of the company Cognition Therapeutics (CGTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Cognition Therapeutics fights neurodegenerative diseases. As in other biotech companies, the company's market capitalization is a bet on the future success of its research. This chart clearly demonstrates how highly the market values the scientific team's potential. Every employee here brings unique knowledge that could lead to the creation of a multi-billion-dollar product.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772513912079 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Cognition Therapeutics develops drugs for the treatment of neurodegenerative diseases targeting beta-amyloid oligomers. This chart reflects the high employee value typical for biotech companies working on Alzheimer's disease, where a scientific breakthrough could lead to a blockbuster.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513912137 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Cognition Therapeutics (CGTX)
Cognition Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases like Alzheimer's by targeting toxic proteins. This is highly complex R&D. This metric is negative. It reflects how much capital the company burns per scientist and doctor in an attempt to solve one of the most complex medical problems of our time.
%20Chart%20Cognition%20Therapeutics%20(CGTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Cognition-Therapeutics-CGTX&v=1772513912159 "Company Profit Per Employee (in thousands of dollars) Chart Cognition Therapeutics (CGTX)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Cognition Therapeutics (CGTX) is a biotech company targeting neurodegenerative diseases such as Alzheimer's. This metric, which reflects sector average profitability, is not yet relevant for CGTX. The company is in the early stages of research. Its entire value lies in the potential of its scientific platform. A successful drug in this field could deliver profitability that exceeds any benchmark.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772513912201 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Cognition Therapeutics (CGTX) fights neurodegenerative diseases such as Alzheimer's. It's a clinical-stage biotech company. Its entire staff is focused on research and testing. This negative metric demonstrates to investors the "value" of the research team and the rate of capital burn in one of the most complex, yet potentially breakthrough, areas of medicine.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513912227 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Cognition Therapeutics (CGTX)
Cognition Therapeutics is a biotech company focused on treating neurodegenerative diseases. This chart shows that the company is in clinical development. Lack of revenue is normal. In the future, this metric will be key to assessing the commercial success of its drugs if they reach the market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Cognition-Therapeutics-CGTX&v=1772513912261 "Sales chart per company employee Cognition Therapeutics (CGTX)")
Sales per employee in the market segment - Neuro
Cognition Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases such as Alzheimer's. During the R&D phase, this metric reflects how effectively their research team generates revenue (e.g., from partnerships) per employee, which is critical for funding long-term research.
Sales per employee for the market as a whole
Cognition Therapeutics is a clinical-stage biotech company focused on treating Alzheimer's disease. It is a 100% R&D business. This chart shows revenue per employee. Since the company has no commercial products, this figure is likely zero. It clearly demonstrates that the company's business is 100% R&D, with a staff of scientists working on future drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Cognition Therapeutics (CGTX)
Cognition Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases such as Alzheimer's. This chart shows bearish bets. Bears are betting on an extremely high risk of failure. The history of development in this field is littered with failures, and investors often bet against companies attempting to solve this complex medical problem.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Cognition-Therapeutics-CGTX&v=1772513912344 "Short Shares Chart for the Company Cognition Therapeutics (CGTX)")
Shares shorted by market segment - Neuro
Cognition Therapeutics develops drugs to treat neurodegenerative diseases such as Alzheimer's. This chart shows the overall short positions in the biotech (neuro) sector. The high short position in this sector reflects the market's intense skepticism due to a long history of failed clinical trials of Alzheimer's drugs.
Shares shorted by the overall market
Cognition Therapeutics (CGTX) is a clinical-stage biotech company working on Alzheimer's disease. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing CGTX will be unable to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Cognition Therapeutics (CGTX)
Cognition Therapeutics is a clinical-stage biotech company working on Alzheimer's disease. The stock is highly speculative. This chart can soar above 70 on positive R&D news. Oversold territory (<30) often reflects setbacks, delays, or general risk aversion in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Cognition-Therapeutics-CGTX&v=1772513912419 "RSI 14 indicator chart for the company's stock Cognition Therapeutics (CGTX)")
RSI 14 Market Segment - Neuro
Cognition (CGTX) — "biotech" versus *Alzheimer's*. The RSI_14_Seg for "Neuro" (biotech) shows the overall sentiment. The chart helps us understand: is CGTX's volatility due to the Alzheimer's "hype" or is the *entire* biotech sector "overheated" (or "oversold")?
RSI 14 for the overall market
Cognition Therapeutics (CGTX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CGTX (Cognition Therapeutics)
Cognition Therapeutics is a biotech company developing oral (tablet-based) drugs for the treatment of neurodegenerative diseases such as Alzheimer's and dementia. This chart shows the analysts' average 12-month forecast, representing their collective speculative bet on the success of clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CGTX-Cognition-Therapeutics&v=1772513912494 "A chart showing analyst consensus forecasts for the expected stock price. CGTX (Cognition Therapeutics)")
The difference between the consensus estimate and the actual stock price CGTX (Cognition Therapeutics)
Cognition Therapeutics (CGTX) is a clinical-stage biotech developing drugs for the treatment of Alzheimer's disease. This chart is a barometer of their R&D. It measures the enormous gap between the speculative price and the consensus target, reflecting the enormous potential analysts see if their therapy is approved.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CGTX-Cognition-Therapeutics&v=1772513912519 "A chart showing the difference between the consensus forecast and the actual stock price. CGTX (Cognition Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Neuro
Cognition Therapeutics is another biotech company trying to crack the Alzheimer's code by developing drugs to protect brain synapses. This chart shows analysts' overall expectations across the neuroscience sector, reflecting whether experts believe breakthroughs in dementia treatments are possible.
Analysts' consensus forecast for the overall market share price
Cognition Therapeutics is a biotech company developing drugs to treat neurodegenerative diseases (Alzheimer's) by targeting receptors in the brain. This chart shows overall risk appetite. For Cognition, which operates in the most complex area of medicine, overall market optimism is critical to funding long-term, expensive trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Cognition Therapeutics
Cognition Therapeutics is a clinical-stage biotech focused on one of the most challenging targets: Alzheimer's disease. They are developing small molecules (pills) that target the toxic proteins that cause brain degeneration. This chart is a clear indicator of faith in their R&D. Its dynamics depend entirely on their (very risky) clinical trial data.
AKIMA Market Segment Index - Neuro
Cognition Therapeutics develops drugs to treat neurodegenerative diseases like Alzheimer's by targeting toxic proteins. This chart shows the average index for the neurosegment. It provides investors with a benchmark for how Cognition's performance, which is working on a complex disease, compares to the sector average.
The AKIM Index for the overall market
Cognition Therapeutics is a biopharmaceutical company developing small molecules to treat age-related diseases (Alzheimer's, AMD). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this clinical-stage research compares to the overall economic trends affecting biotech.
